BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34116173)

  • 1. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.
    Kohyanagi N; Kitamura N; Ikeda S; Shibutani S; Sato K; Ohama T
    J Biol Chem; 2024 Jan; 300(1):105584. PubMed ID: 38141761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
    González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
    Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
    Jiang SW; Xu S; Chen H; Liu X; Tang Z; Cui Y; Liu J
    Clin Chim Acta; 2017 Jan; 464():155-159. PubMed ID: 27836688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
    Kauko O; Westermarck J
    Int J Biochem Cell Biol; 2018 Mar; 96():157-164. PubMed ID: 29355757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
    Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
    Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
    Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
    FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
    Arriazu E; Vicente C; Pippa R; Peris I; Martínez-Balsalobre E; García-Ramírez P; Marcotegui N; Igea A; Alignani D; Rifón J; Mateos MC; Cayuela ML; Nebreda AR; Odero MD
    Blood Cancer J; 2020 Jan; 10(1):3. PubMed ID: 31913266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramide in the prostate.
    Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
    Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
    FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.